Bluebird bio Inc (BLUE) Stock
BLUE is no longer traded. Bluebird bio was delisted from the Nasdaq in May 2025.
Prices on this page are historical; the last trade was May 29, 2025 at $4.97.
Bluebird bio stock price history
BLUE final trading statistics
- Final close
- $4.97
- Final trading day
- May 29, 2025
- Market cap at delisting
- $48.67M
- Shares outstanding
- 9.79M
- Final 52-week range
- $0.29 – $10.28
- Avg. volume (final 3 mo.)
- 556,143
- All-time high (split-adj.)
- $3017.28 · Mar 2018
- All-time low (split-adj.)
- $3.29 · May 2025
- Return since IPO
- -98.6%
- Beta
- 0.36
- Book value / share
- -$5.91
- Price / book
- -0.84
Bluebird bio annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $83.81M | -$240.7M | -$18.75 |
| FY2023 | $29.50M | -$211.9M | -$16.72 |
| FY2022 | $3.60M | -$266.6M | -$4.68 |
| FY2021 | $3.66M | -$562.6M | -$11.80 |
| FY2020 | $250.73M | -$618.7M | -$9.95 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. As of May 29, 2025, bluebird bio, Inc. was taken private.
Bluebird bio stock FAQ
What happened to Bluebird bio stock?
Bluebird bio stock was delisted from the Nasdaq. Its final close was $4.97 on May 29, 2025.
Is BLUE stock still trading?
No. BLUE was delisted from the Nasdaq in May 2025 and no longer trades on a U.S. exchange.
What was the last price of BLUE stock?
BLUE closed at $4.97 on its final trading day, May 29, 2025, for a market value of about $48.67M.
What were Bluebird bio's revenue and earnings in its last full fiscal year?
Bluebird bio reported revenue of $83.81M and net income of -$240.7M in fiscal 2024, its last full year as a public company.
When did Bluebird bio go public?
Bluebird bio Inc stock began trading on June 19, 2013.